Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiolabeled Antimicrobials for Infection Imaging: A Scoping Review.

International journal of molecular sciences·2026
Same author

5' leader defects drive persistent HIV-1 viremia on long-term ART.

Nature communications·2026
Same author

Protocol for the identification of recent HIV infection in newly diagnosed individuals.

STAR protocols·2026
Same author

Safety, immunovirological, and CNS effects of PD-1 inhibition in people with HIV without malignancy.

The Journal of infectious diseases·2026
Same author

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.

Nature medicine·2026
Same author

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.

Science translational medicine·2026
Same journal

Preparation of electroplated zinc-68 targets for gallium-68 cyclotron production using recovered zinc-68.

Nuclear medicine and biology·2026
Same journal

Enhanced pre-therapy dosimetry for SSTR PET: A head-to-head preclinical assessment of [<sup>89</sup>Zr]Zr-DFO-TOC and [<sup>89</sup>Zr]Zr-DFO-TATE.

Nuclear medicine and biology·2026
Same journal

Pharmacokinetics and dosimetry of radiolabeled FAP-targeting single-domain antibody 4AH29 in Göttingen minipigs.

Nuclear medicine and biology·2026
Same journal

Comparative intra-articular retention of [<sup>177</sup>Lu]Lu-MAA and <sup>90</sup>Y resin in a rat knee model.

Nuclear medicine and biology·2026
Same journal

Evaluating the tumour detection efficacy of [<sup>18</sup>F]Fluorthanatrace positron emission tomography in a metastatic lung cancer animal model.

Nuclear medicine and biology·2026
Same journal

Development of a pyrogallol-formaldehyde resin column for one-step pre-purification of <sup>68</sup>Ge/<sup>68</sup>Ga generator eluates: Enhanced [<sup>68</sup>Ga]Ga-DOTA-TATE radiolabeling yield by selective removal of tetravalent cationic impurities.

Nuclear medicine and biology·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

13.9K

Rational development of radiopharmaceuticals for HIV-1.

Chuen-Yen Lau1, Frank Maldarelli1, William C Eckelman2

  • 1National Institutes of Health.

Nuclear Medicine and Biology
|March 11, 2014
PubMed
Summary
This summary is machine-generated.

Developing a targeted radiopharmaceutical for human immunodeficiency virus type 1 (HIV-1) is crucial for identifying infected cells. This approach will aid in assessing viral reservoirs and monitoring treatment response.

Keywords:
Human Immunodeficiency VirusInfectious disease imagingRadiopharmaceutical

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.2K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.0K

Related Experiment Videos

Last Updated: May 2, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

13.9K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

6.2K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.0K

Area of Science:

  • Medical Imaging
  • Virology
  • Radiopharmaceutical Development

Background:

  • The global fight against HIV-1 requires tools to precisely locate infected cells, including those with latent virus.
  • Current methods lack specificity for identifying HIV reservoirs, hindering effective treatment monitoring and management.

Purpose of the Study:

  • To outline the requirements for developing a sensitive and specific radiopharmaceutical for targeting HIV-1-infected cells.
  • To propose a rational development strategy for HIV-1 radiotracers based on viral biology.

Main Methods:

  • Discussing the characteristics of HIV-1 infection that can be targeted by radiopharmaceuticals.
  • Proposing a development pathway involving HIV biology, animal models, and human studies.

Main Results:

  • A rational approach to radiopharmaceutical development is needed, focusing on HIV-specific targets.
  • Potential targets include HIV-specific products, differentially expressed genes, or integrated DNA sequences.

Conclusions:

  • A novel radiopharmaceutical, developed using a rational, biology-driven approach, is essential for clinical and research applications in HIV-1 management.
  • This tool will enable precise assessment of viral reservoirs and monitoring of therapeutic interventions.